sales@dcchemicals.com
Lipid 119-23
Formulation & Performance
Literature-reported formulation composition
| Component | mol% | Role |
|---|---|---|
| 119-23 | Not reported | Ionizable lipid |
| DOPE | Not reported | helper_lipid |
| Cholesterol | Not reported | Sterol |
| C14-PEG | Not reported | PEG lipid |
| Reported total | Not reported | Source values retained |
Formulation calculator unavailable. The supplied article does not report the complete molar composition, so a formulation weight calculation is not available. Obtain and verify the complete composition and component molecular weights before planning component quantities.
Literature-reported performance for the cited formulation
Literature-reported119-23 is identified as outperforming established benchmark lipids in muscle and immune-cell transfection in the publicly visible article abstract.Article-level summary; exact numerical values are not reconstructed from the abstractNature Materials abstract
Literature-reported95 ± 1.5 nm; PDI 0.12 ± 0.02; EE 85.6%Classic four-component 119-23 LNPSI Supplementary Figure 9, public PDF page 18
Literature-reported88 ± 0.01 nm; PDI 0.22 ± 0.01; EE 86.4%119-23 lung-targeted SORT five-component LNPSI Supplementary Figure 9, public PDF page 18
Literature-reportedSerum hEPO was quantified after IV dosing; the SI reports a significant difference for the 119-23/SM-102 comparison (P = 0.0435) and a non-significant 119-23/MC3 comparison (P = 0.9744).0.25 mg/kg hEPO mRNA; n = 3SI Supplementary Figure 7, public PDF page 17
Literature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, model and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
Cited literature for this formulation and performance datasetLi B, Raji IO, Gordon AGR, et al. Accelerating ionizable lipid discovery for mRNA delivery using machine learning and combinatorial chemistry. Nat Mater. 2024;23:1002-1008.
Formulation and performance source locations are listed with the evidence items above.
Formulation and performance source locations are listed with the evidence items above.